Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Hold” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has been assigned an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $16.60.

A number of equities research analysts have recently issued reports on the company. Wall Street Zen lowered Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. B. Riley Financial reduced their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Barclays began coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th.

Insider Buying and Selling at Altimmune

In other news, Director John Gill acquired 12,500 shares of the firm’s stock in a transaction on Tuesday, December 23rd. The stock was bought at an average cost of $4.10 per share, with a total value of $51,250.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at approximately $51,250. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jerome Benedict Durso bought 20,000 shares of the stock in a transaction dated Friday, March 6th. The shares were acquired at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the purchase, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. This represents a 160.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 55,527 shares of company stock worth $213,778 in the last ninety days. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in Altimmune by 13.4% during the 2nd quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock valued at $7,489,000 after purchasing an additional 228,995 shares in the last quarter. Brown Wealth Management LLC increased its holdings in Altimmune by 131.0% during the 2nd quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock worth $894,000 after purchasing an additional 131,059 shares during the last quarter. Intech Investment Management LLC raised its position in shares of Altimmune by 102.9% in the 2nd quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock valued at $561,000 after purchasing an additional 73,482 shares in the last quarter. Jefferies Financial Group Inc. boosted its stake in shares of Altimmune by 40.0% during the 2nd quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock valued at $135,000 after buying an additional 10,000 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Altimmune by 43.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock valued at $826,000 after buying an additional 64,175 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Stock Down 2.8%

Shares of Altimmune stock opened at $3.50 on Friday. The company has a fifty day moving average price of $4.50 and a 200 day moving average price of $4.29. The company has a current ratio of 18.55, a quick ratio of 17.18 and a debt-to-equity ratio of 0.15. Altimmune has a twelve month low of $2.90 and a twelve month high of $7.73. The stock has a market cap of $455.25 million, a price-to-earnings ratio of -3.47 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The company had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. Equities research analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.